Brief: Verastem Oncology Announces Positive Initial Interim Safety And Efficacy Results From RAMP 205 Trial Evaluating Avutometinib Plus Defactinib In Combination With Gemcitabine And NAB-Paclitaxel In First-Line Metastatic Pancreatic Cancer​

Verastem

23/05/2024 23:52

May 23 (Reuters) - Verastem Inc  VSTM.O :
    * VERASTEM ONCOLOGY ANNOUNCES POSITIVE INITIAL INTERIM
SAFETY AND
EFFICACY RESULTS FROM RAMP 205 TRIAL EVALUATING AVUTOMETINIB
PLUS DEFACTINIB IN COMBINATION WITH GEMCITABINE AND
NAB-PACLITAXEL IN FIRST-LINE METASTATIC PANCREATIC CANCER​
    * VERASTEM INC: 83% (5/6) OF PATIENTS ACHIEVED A CONFIRMED
PARTIAL
RESPONSE IN COHORT 1, MOST MATURE DOSE LEVEL
    * VERASTEM INC: ONE DOSE-LIMITING TOXICITY WAS OBSERVED IN
STUDY
    * VERASTEM INC: FOLLOW UP OF PATIENTS IN ADDITIONAL DOSE AND
SCHEDULE COHORTS IS ONGOING TO DETERMINE RECOMMENDED PHASE 2
DOSE FOR STUDY EXPANSION

Source text for Eikon:  ID:nBw7FN3Cha 
Further company coverage:  VSTM.O 

 ((Reuters.Briefs@thomsonreuters.com;))